BioAge Labs, Inc. BIOA · Stock Open BioAge Labs, Inc. in new tab
BioAge Labs, Inc. Analysis (BIOA)
Is BioAge Labs, Inc. a good investment? BioAge Labs, Inc. (BIOA) is currently trading at 10.78 USD. Market analysts have a consensus price target of 49.50 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 1.38. This relatively low multiple may signal that BioAge Labs, Inc. is undervalued compared to historical market norms.
Earnings Schedule: BioAge Labs, Inc. is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -2.04.
Investor FAQ
Does BioAge Labs, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is BioAge Labs, Inc.?
BioAge Labs, Inc. is classified as a Stock.
When is the next earnings date?
The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of -0.87.
Company Profile
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Community Discussion